Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525138 | 1.00 | PEPD (0.48) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL336245 | 1.00 | PEPD (0.48) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL34169 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL130870 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL598373 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL10578737 | 0.95 | PEPD (0.43) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL9663237 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL11660179 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL10739888 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 | |
| SCHEMBL7031195 | 0.93 | PEPD (0.42) | PEPDMEN1BLMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180081273-A1 | RESIN COMPOSITION, METHOD FOR FORMING PATTERN USING THE SAME, AND METHOD FOR SYNTHESIZING POLYMER | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9604977-B2 | Bicyclic thiophenylamide compounds | HOFFMAN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| EP-2861574-B1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20150175594-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014153666-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS, INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| US-7598281-B2 | Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-5886024-A | ENZYME INHIBITOR FOR TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5874473-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS | BAYER CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861427-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, CONDITIONS LEADING TO INFLAMMATORY | BAYER HEALTHCARE LLC | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4206137-A | Thioalkanoylalkanoic acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | PEPD 361/4885MEN1 1148/4885BLM 1238/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | PEPD 361/4885MEN1 1148/4885BLM 1238/4885 |
| US-20150175594-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | NAT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BICRA | PEPD 3278/4885MEN1 1427/4885BLM 1726/4885 |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | PEPD 361/4885MEN1 1148/4885BLM 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.